These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38311733)

  • 1. ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway.
    Xu J; Wu F; Zhu Y; Wu T; Cao T; Gao W; Liu M; Qian W; Feng G; Xi X; Hou S
    Cancer Cell Int; 2024 Feb; 24(1):54. PubMed ID: 38311733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.
    Li YK; Gao AB; Zeng T; Liu D; Zhang QF; Ran XM; Tang ZZ; Li Y; Liu J; Zhang T; Shi GQ; Zhou WC; Zou WD; Peng J; Zhang J; Li H; Zou J
    J Transl Med; 2024 Jan; 22(1):46. PubMed ID: 38212795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulation of angiopoietin-like 4 slows ovarian cancer progression through vascular endothelial growth factor receptor 2 phosphorylation.
    Wu Y; Gao J; Liu X
    Cancer Cell Int; 2021 Mar; 21(1):171. PubMed ID: 33726754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANGPTL4 functions as an oncogene through regulation of the ETV5/CDH5/AKT/MMP9 axis to promote angiogenesis in ovarian cancer.
    Liu Y; Yang R; Zhang Y; Zhu Y; Bao W
    J Ovarian Res; 2022 Dec; 15(1):131. PubMed ID: 36517864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
    Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
    J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Guo W; Sun Z; Zhao N; Zhou Y; Ren J; Huang L; Ping Y
    Ann Transl Med; 2021 Nov; 9(22):1669. PubMed ID: 34988178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway.
    Han FJ; Li J; Shen Y; Guo Y; Liu YC; Yu Y; Xu JY; Liu SX; Wang YH
    J Ovarian Res; 2020 Sep; 13(1):110. PubMed ID: 32948241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
    Wu Y; Wang T; Xia L; Zhang M
    Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
    Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
    J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
    Liu H; Shi H; Fan Q; Sun X
    Tumour Biol; 2016 Aug; 37(8):10161-75. PubMed ID: 26831658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPX2 gene silencing inhibits cell proliferation and promotes apoptosis through negative regulation of AKT signaling pathway in ovarian cancer.
    Tian Y; Liu LL; Guo DM; Wang Y; Zha WH; Li Y; Wu FJ
    J Cell Biochem; 2018 Sep; 119(9):7540-7555. PubMed ID: 29904936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiopoietin-like 4 confers resistance to hypoxia/serum deprivation-induced apoptosis through PI3K/Akt and ERK1/2 signaling pathways in mesenchymal stem cells.
    Hou M; Cui J; Liu J; Liu F; Jiang R; Liu K; Wang Y; Yin L; Liu W; Yu B
    PLoS One; 2014; 9(1):e85808. PubMed ID: 24465718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies.
    Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C
    J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.
    Hu K; Babapoor-Farrokhran S; Rodrigues M; Deshpande M; Puchner B; Kashiwabuchi F; Hassan SJ; Asnaghi L; Handa JT; Merbs S; Eberhart CG; Semenza GL; Montaner S; Sodhi A
    Oncotarget; 2016 Feb; 7(7):7816-28. PubMed ID: 26761211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
    Yuan S; Xu Y; Yi T; Wang H
    J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of long non‑coding RNA CCEPR is associated with poor prognosis and contributes to the progression of ovarian cancer through regulating the Wnt/β‑catenin signaling pathway.
    Chen Z; Zhu Y; Fan X; Liu Y; Feng Q
    Mol Med Rep; 2020 Apr; 21(4):1950-1958. PubMed ID: 32319633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FBXL18 is required for ovarian cancer cell proliferation and migration through activating AKT signaling.
    Zhuang Y; Xue J; Qiu X; Zhu Y; Lv J; Xia F
    Am J Transl Res; 2024; 16(5):1977-1990. PubMed ID: 38883375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.
    Liu T; Shen J; He Q; Xu S
    Front Genet; 2022; 13():814291. PubMed ID: 35237300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis.
    Li C; Wang Q; Luo Y; Xiang J
    Anal Cell Pathol (Amst); 2022; 2022():5632164. PubMed ID: 36247876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of a novel glycolysis-related gene signature for predicting the prognosis in ovarian cancer.
    Yu J; Liu TT; Liang LL; Liu J; Cai HQ; Zeng J; Wang TT; Li J; Xiu L; Li N; Wu LY
    Cancer Cell Int; 2021 Jul; 21(1):353. PubMed ID: 34229669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.